A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Exclusion Criteria

• •Has any unstable or progressive SLE manifestation (example: central nervous system lupus, systemic vasculitis, end-stage renal disease, severe or rapidly progressive glomerulonephritis, pulmonary hemorrhage, myocarditis) that may warrant escalation in therapy beyond permitted background medications. Participants requiring renal hemodialysis or peritoneal dialysis are also excluded
• •Has other co-existent inflammatory diseases (example: rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease)
• •Has a urinary protein to creatinine ratio of greater than (\>)4 gram per gram (g/g) per day
• •Has an acute or chronic infectious illness (example: human immunodeficiency virus, hepatitis B or C virus, tuberculosis, opportunistic infections)
• •Has a history of cancer or lymphoproliferative disease within the last 5 years except for treated and non-recurrent cutaneous basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma
• •Has any condition requiring multiple courses of systemic glucocorticoids (example: uncontrolled asthma, chronic obstructive pulmonary disease)
• •Has a history of major surgery within the last month
• •Has received live virus or bacterial vaccines within 16 weeks prior to first dose of study agent or Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening
• •Has previously received ustekinumab
• •Has received cyclophosphamide orally within 90 days or intravenously within 180 days of screening
• •Has received a single B-cell targeted therapy (e.g. belimumab) within 3 months, \>1 previous B-cell targeted therapy within 6 months, or B-cell depleting therapy (example: rituximab) within 12 months of first dose of study agent
• •Has received protocol-prohibited oral or biologic immunomodulatory therapy in the last 3 months or less than (\<)5 half-lives (whichever is longer) prior to first dose of study agent
• •Has received adrenocorticotropic hormone (ACTH) within 1 month prior to first dose of study agent
• •Has received epidural, intravenous, intramuscular, intraarticular, intrabursal, intralesional glucocorticoids within 6 weeks of first dose of study agent
• •Locally-delivered therapies except for ophthalmic use of cyclosporine A or topical use of nonsteroidal anti inflammatory drugs (NSAIDs), analgesics, or high-potency glucocorticoids (World Health Organization criteria) are prohibited